Get startedLog in
    Picture of Basilea Pharmaceutica AG, Allschwil logo

    BSLN — Basilea Pharmaceutica AG, Allschwil News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareAdventurousMid CapHigh Flyer
    All News

    Brief: Basilea Receives Additional USD 5.4 Million From Barda To Continue Development Of Novel Antibiotic Ceftibuten-Ledaborbactam

    Picture of Basilea Pharmaceutica AG, Allschwil logoBasilea Pharmaceutica AG, Allschwil
    05/08/2026 06:16
    BRIEF-Basilea Receives Additional USD 5.4 Million From Barda To Continue Development Of Novel Antibiotic Ceftibuten-Ledaborbactam
    Aug 5 (Reuters) - BASILEA PHARMACEUTICA AG, Allschwil BSLN.S:
    • RECEIVES ADDITIONAL USD 5.4 MILLION FROM BARDA TO CONTINUE DEVELOPMENT OF NOVEL ANTIBIOTIC CEFTIBUTEN-LEDABORBACTAM
    Source text: ID:nGNX1jTk6g
    Further company coverage: BSLN.S

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Basilea Pharmaceutica AG, Allschwil

    See all news